Alkermes plc, formed by the merger of Waltham, MA-based Alkermes, Inc. and Elan Drug Technologies (EDT), is a fully integrated global biopharmaceutical company that utilizes proprietary technologies to research, develop and commercialize, both with partners and on its own pharmaceutical products in major therapeutic areas. Alkermes holds a diversified product portfolio and a promising pipeline of candidates targeting major central nervous system (CNS) disorders including schizophrenia, depression, addiction and multiple sclerosis. Alkermes derives revenues on net sales of its proprietary products: Vivitrol & Aristada, and manufacturing and/or royalty revenues on net sales of products commercialized by the company's partners. These include Risperdal Consta, Invega Sustenna/Xeplion, Invega Trinza/Trevicta, Ampyra/Fampyra and Bydureon. Interesting late-stage candidate in the company's pipeline include nemvaleukin alfa developed for treating advanced solid tumors. Its proprietary drugs are Vivitrol & Aristada....
+See More2019-04-03 11:35:00 Wednesday ET
A Florida fintech group Fidelity Information Services initiates the largest $43 billion acquisition of the e-commerce payments processor Worldpay. Fidelity
2020-09-17 12:28:00 Thursday ET
Many successful business organizations develop their distinctive capabilities and unique value propositions for strategic reasons. Paul Leinwand and Cesa
2019-07-23 09:22:00 Tuesday ET
Harvard economic platform researcher Dipayan Ghosh proposes some alternative solutions to breaking up tech titans such as Facebook, Google, Apple, and Amazo
2019-10-19 16:35:00 Saturday ET
European economic integration seems to have gone backwards primarily due to the recent Brexit movement. Brexit, key European sovereign debt, and French and
2019-08-01 11:33:00 Thursday ET
Many young and mid-career Americans fall into the financial distress trap in rural communities. A recent analysis of 25,800 zip codes for 99% of the U.S. po
2019-08-22 11:35:00 Thursday ET
Fundamental factors often reflect macroeconomic innovations and so help inform better stock investment decisions. Nobel Laureate Eugene Fama and his long-ti